

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

APPOINTMENT OF AN EXECUTIVE DIRECTOR

APPOINTMENT OF AN EXECUTIVE DIRECTOR

The Board announces that with effect from 11 August 2023:

Ms. Zhang Yanfen (“**Ms. Zhang**”) has been appointed as an executive Director.

The biographical details of Ms. Zhang is set out below:

Ms. Zhang, aged 44, obtained a junior college degree in Business Administration from Jilin College of Business Administration.

Ms. Zhang has over 20 years of experience in management and marketing. Ms. Zhang is a 100% controlling shareholder of Shenzhen Meilsee Aesthetic Medical Clinic (深圳美洛斯醫療美容門診部) from 2018 to 2023, a 100% controlling shareholder of Shenzhen Jinli Aesthetic Medical Clinic (深圳金麗醫療美容門診部) from 2014 to 2023, a shareholder and person responsible for general operation of Shenzhen Aodai Lier Beauty Technology Co., Ltd. (深圳奧黛麗爾美容科技有限公司) from 2013 to 2018. Ms. Zhang is a general manager of operations of Midea Shenzhen Branch (美的深圳分公司) from 2000 to 2012 and a person in charge of investment promotion in Hunchun 98 Tumen River (琿春98圖們江) from 1997 to 1999.

* For identification purposes only

Save as disclosed above, as at the date of this announcement, Ms. Zhang does not have any relationship with any director, senior management, substantial shareholders or controlling shareholders (having the meaning ascribed to it in the Listing Rules) of the Company. Save as disclosed above, Ms. Zhang (i) does not hold any other major appointment and qualifications or any directorship in other listed companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (ii) does not hold any other positions with the Company or other members of the Group.

As at the date of this announcement, Ms. Zhang does not have any interest in the shares or underlying shares within the meaning of Part XV of the SFO.

Pursuant to the service agreement entered into between Ms. Zhang and the Company, Ms. Zhang has been appointed as an executive Director for a term of three years commencing from 11 August 2023. Ms. Zhang would be subject to retirement by rotation and re-election at the annual general meeting in accordance with the articles of association of the Company and Ms. Zhang has no fixed remuneration but she is entitled to receive director fee determined by the Board from time to time based on her performance, experience, responsibilities and prevailing market conditions.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Ms. Zhang that need to be brought to the attention of the shareholders of the Company, or any other information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to welcome Ms. Zhang to join the Board.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 11 August 2023

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang and Ms. Zhang Yanfen; one non-executive Director, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.